These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38861891)

  • 1. Reductions of food intake and body weight in diet-induced obese rats following chronic treatment with a monomeric peptide multiagonist.
    Elfers CT; Chichura KS; Ashlaw EF; Chepurny OG; Holz GG; Doyle RP; Roth CL
    Clin Nutr; 2024 Jul; 43(7):1782-1790. PubMed ID: 38861891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The novel chimeric multi-agonist peptide (GEP44) reduces energy intake and body weight in male and female diet-induced obese mice in a glucagon-like peptide-1 receptor-dependent manner.
    Blevins JE; Honeycutt MK; Slattery JD; Goldberg M; Rambousek JR; Tsui E; Dodson AD; Shelton KA; Salemeh TS; Elfers CT; Chichura KS; Ashlaw EF; Zraika S; Doyle RP; Roth CL
    Front Endocrinol (Lausanne); 2024; 15():1432928. PubMed ID: 39104812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Novel Chimeric Multi-Agonist Peptide (GEP44) Reduces Energy Intake and Body Weight in Male and Female Diet-Induced Obese Mice in a Glucagon-Like Peptide-1 Receptor-Dependent Manner.
    Blevins JE; Honeycutt MK; Slattery JD; Goldberg M; Rambousek JR; Tsui E; Dodson AD; Shelton KA; Salemeh TS; Elfers CT; Chichura KS; Ashlaw EF; Zraika S; Doyle RP; Roth CL
    bioRxiv; 2024 May; ():. PubMed ID: 38826286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
    Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
    Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile.
    Larsen AT; Gydesen S; Sonne N; Karsdal MA; Henriksen K
    BMC Endocr Disord; 2021 Jan; 21(1):10. PubMed ID: 33413317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Elvert R; Herling AW; Bossart M; Weiss T; Zhang B; Wenski P; Wandschneider J; Kleutsch S; Butty U; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Lorenz M; Keil S; Larsen PJ
    Diabetes Obes Metab; 2018 Aug; 20(8):1836-1851. PubMed ID: 29938884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and Evaluation of Peptide Dual-Agonists of GLP-1 and NPY2 Receptors for Glucoregulation and Weight Loss with Mitigated Nausea and Emesis.
    Milliken BT; Elfers C; Chepurny OG; Chichura KS; Sweet IR; Borner T; Hayes MR; De Jonghe BC; Holz GG; Roth CL; Doyle RP
    J Med Chem; 2021 Jan; 64(2):1127-1138. PubMed ID: 33449689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of the long-acting GLP-1 receptor ligands, liraglutide and exendin-4, on food intake and body weight suppression in rats.
    Hayes MR; Kanoski SE; Alhadeff AL; Grill HJ
    Obesity (Silver Spring); 2011 Jul; 19(7):1342-9. PubMed ID: 21415845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Team Players or Opponents: Coadministration of Selective Glucagon and GLP-1 Receptor Agonists in Obese Diabetic Monkeys.
    Elvert R; Bossart M; Herling AW; Weiss T; Zhang B; Kannt A; Wagner M; Haack T; Evers A; Dudda A; Keil S; Lorenz M; Lorenz K; Riz M; Hennerici W; Larsen PJ
    Endocrinology; 2018 Aug; 159(8):3105-3119. PubMed ID: 29992313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
    Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
    Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
    Mashayekhi M; Nian H; Mayfield D; Devin JK; Gamboa JL; Yu C; Silver HJ; Niswender K; Luther JM; Brown NJ
    Diabetes; 2024 Jan; 73(1):38-50. PubMed ID: 37874653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-YY
    Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
    Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease.
    Han C; Sun Y; Yang Q; Zhou F; Chen X; Wu L; Sun L; Han J
    Mol Pharm; 2021 Aug; 18(8):2906-2923. PubMed ID: 34240881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liraglutide shows superior cardiometabolic benefits than lorcaserin in a novel free choice diet-induced obese rat model.
    Briand F; Brousseau E; Maupoint J; Dubroca C; Costard C; Breyner N; Burcelin R; Sulpice T
    Eur J Pharmacol; 2020 Sep; 882():173316. PubMed ID: 32621913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A peptide triple agonist of GLP-1, neuropeptide Y1, and neuropeptide Y2 receptors promotes glycemic control and weight loss.
    Chichura KS; Elfers CT; Salameh TS; Kamat V; Chepurny OG; McGivney A; Milliken BT; Holz GG; Applebey SV; Hayes MR; Sweet IR; Roth CL; Doyle RP
    Sci Rep; 2023 Jun; 13(1):9554. PubMed ID: 37308546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
    Hansen G; Jelsing J; Vrang N
    Acta Pharmacol Sin; 2012 Feb; 33(2):194-200. PubMed ID: 22301859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDF15 acts synergistically with liraglutide but is not necessary for the weight loss induced by bariatric surgery in mice.
    Frikke-Schmidt H; Hultman K; Galaske JW; Jørgensen SB; Myers MG; Seeley RJ
    Mol Metab; 2019 Mar; 21():13-21. PubMed ID: 30685336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats.
    Krieger JP; Langhans W; Lee SJ
    Physiol Behav; 2018 Aug; 192():194-199. PubMed ID: 29654813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The enduring metabolic improvement of combining dual amylin and calcitonin receptor agonist and semaglutide treatments in a rat model of obesity and diabetes.
    Larsen AT; Mohamed KE; Melander SA; Karsdal MA; Henriksen K
    Am J Physiol Endocrinol Metab; 2024 Aug; 327(2):E145-E154. PubMed ID: 38864815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss.
    Liberini CG; Koch-Laskowski K; Shaulson E; McGrath LE; Lipsky RK; Lhamo R; Ghidewon M; Ling T; Stein LM; Hayes MR
    Sci Rep; 2019 Jun; 9(1):8447. PubMed ID: 31186439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.